多巴胺及其受体在儿童抽动障碍中的作用

邱佳琪; 钟霞; 邹时朴

doi:10.11852/zgetbjzz2024-0151

PDF(597 KB)

中国儿童保健杂志 ›› 2024, Vol. 32 ›› Issue (10) : 1097-1100. DOI: 10.11852/zgetbjzz2024-0151

综述

多巴胺及其受体在儿童抽动障碍中的作用

邱佳琪 ^1,2, 钟霞¹, 邹时朴¹

作者信息 +

Role of dopamine and its receptors in tic disorder in children

QIU Jiaqi ^1,2, ZHONG Xia¹, ZOU Shipu¹

Author information +

文章历史 +

摘要

抽动障碍是以运动和/或发声抽动为特征的在儿童期发作的神经精神障碍,通常影响儿童的身心健康。抽动障碍的发病机制可能与皮质-纹状体-丘脑-皮质回路中的异常神经递质有关,尤其是儿茶酚胺类神经递质多巴胺。本文针对重要神经递质多巴胺及其受体在抽动障碍发病中的作用展开综述,以期为指导临床治疗和预防提供参考。

Abstract

Tic disorder is a childhood-onset neuropsychiatric disorder characterized by motor and/or vocal tics that commonly affect children′s physical and mental health.The pathogenesis of tic disorders may be related to abnormal neurotransmitters in the cortico-striatal-thalamic-cortical loop, especially the catecholamine neurotransmitter dopamine. This article reviews the role of dopamine and its receptors in the pathogenesis of tic disorders, in order to provide reference for clinical treatment and prevention.

导出引用

邱佳琪 , 钟霞, 邹时朴. 多巴胺及其受体在儿童抽动障碍中的作用[J]. 中国儿童保健杂志. 2024, 32(10): 1097-1100 https://doi.org/10.11852/zgetbjzz2024-0151

QIU Jiaqi , ZHONG Xia, ZOU Shipu. Role of dopamine and its receptors in tic disorder in children[J]. Chinese Journal of Child Health Care. 2024, 32(10): 1097-1100 https://doi.org/10.11852/zgetbjzz2024-0151

中图分类号： R749.94

参考文献

[1] Ramteke A, Lamture Y. Tics and Tourette syndrome: A literature review of etiological, clinical, and pathophysiological aspects[J]. Cureus, 2022,14(8):e28575.
[2] McGuire JF, Piacentini J, Storch EA, et al. Defining tic severity and tic impairment in Tourette disorder[J]. J Psychiatr Res, 2021,133:93-100.
[3] 姜妍琳, 张蔷, 翟睿, 等. 中国儿童抽动障碍患病率及危险因素系统评价[J]. 中国儿童保健杂志, 2023,31(6):661-667.
Jiang YL,Zhang Q,Zhai R,et al. Systematic review of the prevalence and risk factors of tic Chinese children[J]. Chin J Child Health Care, 2023,31 (6): 661-667.(in Chinese)
[4] Liu ZS, Cui YH, Sun D, et al. Current Status, diagnosis, and treatment recommendation for tic disorders in China[J]. Front Psychiatry, 2020,11:774.
[5] Kong L, Lv B, Wu T, et al. Altered structural cerebral cortex in children with Tourette syndrome[J]. Eur J Radiol, 2020,129:109119.
[6] Klein MO, Battagello DS, Cardoso AR, et al. Dopamine: Functions, signaling, and association with neurological diseases[J]. Cell Mol Neurobiol, 2019,39(1):31-59.
[7] Davis SE, Cirincione AB, Jimenez-Torres AC, et al. The impact of neurotransmitters on the neurobiology of neurodegenerative diseases[J]. Int J Mol Sci, 2023,24(20):15340.
[8] Misganaw D. Heteromerization of dopaminergic receptors in the brain: pharmacological implications[J]. Pharmacol Res, 2021,170:105600.
[9] Speranza L, di Porzio U, Viggiano D, et al. Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control[J]. Cells, 2021,10(4):735.
[10] Felsing DE, Jain MK, Allen JA. Advances in dopamine D₁ receptor ligands for neurotherapeutics[J]. Curr Top Med Chem, 2019,19(16):1365-1380.
[11] Martel JC, Gatti McArthur S. Dopamine receptor subtypes, physiology and pharmacology: New ligands and concepts in schizophrenia[J]. Front Pharmacol, 2020,11:1003.
[12] Buse J, Schoenefeld K, Munchau A, et al. Neuromodulation in Tourette syndrome: Dopamine and beyond[J]. Neurosci Biobehav Rev, 2013,37(6):1069-1084.
[13] Maia TV, Conceição VA. Dopaminergic disturbances in Tourette syndrome: An integrative account[J]. Biol Psychiatry. 2018,84(5):332-344.
[14] Terao Y, Nomura Y, Fukuda H, et al. The pathophysiology of Gilles de la Tourette Syndrome: Changes in saccade performance by low-dose L-Dopa and dopamine receptor blockers[J]. Brain Sci, 2023,13(12):1634.
[15] Maia TV, Conceição VA. The roles of phasic and tonic dopamine in tic learning and expression[J]. Biol Psychiatry, 2017,82(6):401-412.
[16] Ernst M, Zametkin AJ, Jons PH, et al. High presynaptic dopaminergic activity in children with Tourette′s disorder[J]. J Am Acad Child Adolesc Psychiatry, 1999,38(1):86-94.
[17] Cheon KA, Ryu YH, Namkoong K, et al. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette′s disorder[J]. Psychiatry Res, 2004,130(1):85-95.
[18] Iverson AM, Black KJ. Why tic severity changes from then to now and from here to there[J]. J Clin Med, 2022,11(19):5930.
[19] Tan CY, Chiu N, Zeng Y, et al. Psychosocial stress in children with Tourette syndrome and chronic tic disorder[J]. Pediatr Neonatol, 2023,S1875-9572(23)00210-3.
[20] Lamanna J, Ferro M, Spadini S, et al. The dysfunctional mechanisms throwing tics: structural and functional changes in Tourette syndrome[J]. Behav Sci (Basel), 2023,13(8):668.
[21] Hsu CJ, Wong LC, Lee WT. Immunological dysfunction in Tourette syndrome and related disorders[J]. Int J Mol Sci, 2021,22(2):853.
[22] Schrag A, Martino D, Apter A, et al. European Multicentre Tics in Children Studies (EMTICS): Protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents[J]. Eur Child Adolesc Psychiatry, 2019,28(1):91-109.
[23] Wang HC, Lau CI, Lin CC, et al. Group a streptococcal infections are associated with increased risk of pediatric neuropsychiatric disorders: A Taiwanese population-based cohort study[J]. J Clin Psychiatry, 2016,77(7):e848-e854.
[24] Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part Ⅲ: pharmacological treatment[J]. Eur Child Adolesc Psychiatry, 2022,31(3):425-441.
[25] Doobay M, Sharma V, Eccles H. Antiseizure medication-induced obsessive-compulsive disorder and tic disorder: A pragmatic review[J]. Expert Rev Neurother, 2022,22(8):721-731.
[26] 孙云云, 韩斐, 杨晴晴, 等. 共患和不共患ADHD的抽动障碍患儿临床特征调查分析[J]. 中国儿童保健杂志, 2021,29(1):97-100,105.
Sun YY, Han F, Yang QQ, et al. Iclinical investigation analysis of tic disorder in children with and without attention defict hyperactivity dsiorder[J]. Chin J Child Health Care, 2021,29 (1): 97-100,105.(in Chinese)
[27] Rothenberger A, Heinrich H. Co-occurrence of tic disorders and attention-deficit/hyperactivity disorder-does it reflect a common neurobiological background?[J]. Biomedicines, 2022,10(11):2950.
[28] Kumar A, Trescher W, Byler D. Tourette syndrome and comorbid neuropsychiatric conditions[J]. Curr Dev Disord Rep, 2016,3(4):217-221.
[29] Cox JH, Cavanna AE. Aripiprazole for the treatment of Tourette syndrome[J]. Expert Rev Neurother, 2021,21(4):381-391.
[30] 辛莹莹, 石亮, 梅艳,等. 阿立哌唑治疗抽动障碍的药动学研究进展[J]. 药物流行病学杂志, 2023,32(2):221-226.
Xin YY, Shi L, Mei Y, et al. Progress of the pharmacokinetics for aripiprazole in the treatment of tic disorder[J]. Chin J Pharmacoepidemiol, 2023,32(2): 221-226.(in Chinese)
[31] 李丽嫱, 陈娜, 高宝勤, 等. 硫必利联合羚羊角胶囊治疗儿童抽动秽语综合征[J]. 长春中医药大学学报, 2019,35(3):476-479.
Li LQ, Chen N, Gao BQ, et al. Effect and mechanism of tiapride combined with lingyangjiao capsule in the treatment of Tourette syndrome in children[J]. J Changchun Univ Tradit Chin Med, 2019,35(3): 476-479.(in Chinese)
[32] 卢青, 孙丹, 刘智胜. 中国抽动障碍诊断和治疗专家共识解读[J]. 中华实用儿科临床杂志, 2021,36(9):647-653.
Lu Q, Sun D, Liu ZS. Interpretation expert consensus for diagnosis and treatment of tic disorder in China[J]. Chin J Appl Clin Pediatr, 2021,36 (9): 647-653.(in Chinese)
[33] Mogwitz S, Buse J, Wolff N, et al. Update on the pharmacological treatment of tics with dopamine-modulating agents[J]. ACS Chem Neurosci, 2018,9(4):651-672.
[34] Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of Tourette syndrome[J]. CNS Drugs, 2018,32(1):33-45.
[35] Gilbert DL, Murphy TK, Jankovic J, et al. Ecopipam, a D₁ receptor antagonist, for treatment of Tourette syndrome in children: A randomized, placebo-controlled crossover study[J]. Mov Disord, 2018,33(8):1272-1280.
[36] Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette syndrome: A randomized trial[J]. Pediatrics, 2023,151(2):e2022059574.